Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference79 articles.
1. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group;Hehlmann;Blood,1993
2. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy;Kantarjian;Ann Intern Med,1995
3. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia;Guilhot;N Engl J Med,1997
4. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR–ABL positive cells;Druker;Nat Med,1996
5. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia;Kantarjian;N Engl J Med,2002
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers;Clinical and Translational Science;2024-09
2. Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia;International Journal of Hematologic Oncology;2022-06
3. Higher red blood cell distribution width at diagnose is a simple negative prognostic factor in chronic phase-chronic myeloid leukemia patients treated with tyrosine kinase inhibitors;Medicine;2021-03-12
4. Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells;Biochemical and Biophysical Research Communications;2020-05
5. Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia;American Journal of Clinical Oncology;2020-04-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3